Company Overview and News
KUALA LUMPUR: Malaysian Bulk Carriers Bhd (Maybulk), which is controlled by tycoon Tan Sri Robert Kuok Hock Nien, saw its second-quarter net loss expand about 14 times year-on-year to RM151.27 million from RM10.75 million, as it recognised an impairment loss from the disposal of its associate, Singapore-listed PACC Offshore Services Holdings Ltd (POSH).
KUALA LUMPUR (Aug 23): Based on corporate announcements and news flow today, companies that will be in focus on Friday (Aug 24) may include: Sime Darby Plantation Bhd, Axiata Group Bhd, Malakoff Corp Bhd, Pestech International Bhd, Censof Holdings Bhd, Hibiscus Petroleum Bhd, S P Setia Bhd, Malaysian Bulk Carriers Bhd, Malaysian Pacific Industries Bhd and Tropicana Corp Bhd.
5347 3867 6888 TNABY 5219 5077 8664 AXXTF TNABF 5195 HIPEF 5199
KUALA LUMPUR(Aug 23): Malaysian Bulk Carriers Bhd (Maybulk), which is controlled by tycoon Robert Kuok, saw its second quarter net loss expand about 14 times year-on-year to RM151.27 million from RM10.75 million, as it recognised an impairment loss from the disposal of its former associate, Singapore-listed PACC Offshore Services Holdings Ltd (POSH).
PETALING JAYA: Malaysian Bulk Carriers Bhd (Maybulk) plans to sell its entire 21.23% stake in Singapore-listed PACC Offshore Services Holdings Ltd (POSH) to its own shareholders, as the firm seeks to raise cash to pay for new vessels and cut down its debts.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...